What is Mesh Bio?
Mesh Bio is a digital health startup dedicated to addressing the increasing clinical challenges posed by metabolic diseases, particularly those exacerbated by an aging population and complex care delivery systems. The company develops advanced clinical decision support analytics and automation solutions specifically designed for the management of chronic conditions, including cardiovascular disease. Its proprietary DARA® Health Intelligence Platform is engineered to facilitate data-driven care delivery, aiming to enhance patient engagement and ultimately improve health outcomes through intelligent insights and automated processes.
How much funding has Mesh Bio raised?
Mesh Bio has raised a total of $5.3M across 2 funding rounds:
Angel/Seed
$1.8M
Series A
$3.5M
Angel/Seed (2021): $1.8M with participation from Elev8.vc, Tael Partners, SEED Capital, and CITRINE CAPITAL
Series A (2024): $3.5M led by East Ventures
Key Investors in Mesh Bio
East Ventures
East Ventures is a prominent venture capital firm in Southeast Asia, focusing on supporting visionary founders from Seed to Growth stages. With over 300 portfolio companies, the firm emphasizes sustainable development and social impact through ESG-driven initiatives.
Elev8.vc
Elev8.vc is an investment firm that participates in early-stage funding rounds, supporting innovative startups in their initial growth phases.
Tael Partners
Tael Partners is an investment entity that provides capital to emerging companies, contributing to their development and market entry.
What's next for Mesh Bio?
With the recent major strategic investment, Mesh Bio is poised for accelerated growth and market expansion. The company's focus on chronic disease management, particularly for metabolic and cardiovascular conditions, aligns with critical healthcare needs. This latest round of financing will likely fuel further development of its DARA® Health Intelligence Platform, enabling broader adoption by healthcare providers and potentially expanding its reach into new therapeutic areas or geographical markets. The strategic backing suggests a trajectory towards scaling operations and solidifying its position as a key player in the digital health analytics space.
See full Mesh Bio company page
